NovoCure Limited (NVCR) Insider Eilon D. Kirson Sells 22,269 Shares
NovoCure Limited (NASDAQ:NVCR) insider Eilon D. Kirson sold 22,269 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $22.01, for a total transaction of $490,140.69. Following the completion of the transaction, the insider now owns 63,120 shares in the company, valued at $1,389,271.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NovoCure Limited (NASDAQ:NVCR) last released its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. The firm had revenue of $50.10 million during the quarter, compared to the consensus estimate of $43.45 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. NovoCure Limited’s revenue was up 130.9% compared to the same quarter last year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/02/novocure-limited-nvcr-insider-eilon-d-kirson-sells-22269-shares.html.
A number of institutional investors have recently added to or reduced their stakes in the stock. Hodges Capital Management Inc. purchased a new stake in NovoCure Limited in the third quarter valued at approximately $4,178,000. Chicago Equity Partners LLC grew its holdings in NovoCure Limited by 57.4% in the third quarter. Chicago Equity Partners LLC now owns 101,795 shares of the medical equipment provider’s stock valued at $2,021,000 after purchasing an additional 37,110 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in NovoCure Limited by 23.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 29,565 shares of the medical equipment provider’s stock valued at $587,000 after purchasing an additional 5,610 shares during the period. Frontier Capital Management Co. LLC grew its holdings in NovoCure Limited by 0.8% in the third quarter. Frontier Capital Management Co. LLC now owns 833,576 shares of the medical equipment provider’s stock valued at $16,546,000 after purchasing an additional 6,522 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new stake in NovoCure Limited in the third quarter valued at approximately $1,637,000. Hedge funds and other institutional investors own 36.20% of the company’s stock.
Several equities analysts have recently commented on the stock. Deutsche Bank AG restated a “hold” rating and issued a $19.00 price objective (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. BidaskClub upgraded shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Mizuho assumed coverage on shares of NovoCure Limited in a report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and issued a $25.00 price objective (down from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. NovoCure Limited presently has an average rating of “Buy” and an average target price of $21.00.
About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.